Home » Stocks » MDGL

Madrigal Pharmaceuticals, Inc. (MDGL)

Stock Price: $109.04 USD -4.96 (-4.35%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 1.69B
Revenue (ttm) n/a
Net Income (ttm) -170.86M
Shares Out 15.45M
EPS (ttm) -11.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $109.04
Previous Close $114.00
Change ($) -4.96
Change (%) -4.35%
Day's Open 112.72
Day's Range 108.61 - 115.93
Day's Volume 147,739
52-Week Range 60.13 - 133.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 month ago

In November, Madrigal released open label data from the MAESTRO-NAFLD study. This data was positive, and could be used to make predictions about the entire study.

GlobeNewsWire - 2 months ago

CONSHOHOCKEN, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced that Dr. Stephen Harrison, M.D., Medical Director for Pinnacle Clinical Research, S...

GlobeNewsWire - 2 months ago

CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetir...

InvestorPlace - 2 months ago

When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades ap...

Other stocks mentioned: AXSM, NKLA, TLRY
GlobeNewsWire - 3 months ago

CONSHOHOCKEN, Pa., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced today that, based on data from studies with MGL-3196 (resmetirom), three posters an...

GlobeNewsWire - 4 months ago

CONSHOHOCKEN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has already exceeded the originally targeted enrollment of 700 pati...

GlobeNewsWire - 4 months ago

CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™...

GlobeNewsWire - 5 months ago

CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights:

The Motley Fool - 6 months ago

These two companies are going after the same target, but which one should you bet on today?

Other stocks mentioned: ICPT
Investors Business Daily - 7 months ago

Madrigal Pharmaceuticals sees its Relative Strength Rating enter the 80-plus level. The post Madrigal Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on Investor...

The Motley Fool - 7 months ago

They have one big thing in common: great growth prospects.

Other stocks mentioned: BMY, VRTX
Seeking Alpha - 8 months ago

Madrigal's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: IVC, MRNA
GlobeNewsWire - 9 months ago

-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patien...

Seeking Alpha - 9 months ago

Madrigal: A Stellar Stock For This Coronavirus Bear Market

GuruFocus - 9 months ago

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belon...

Other stocks mentioned: BMY, GNFT, ICPT, NVS, PTCT, RHHBY
The Motley Fool - 10 months ago

These companies are developing drugs that target the one of the biggest threats from the obesity epidemic.

Other stocks mentioned: ICPT
Seeking Alpha - 11 months ago

Impressive cash position.

24/7 Wall Street - 11 months ago

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has seen more than its share of volatility over the past year.

Seeking Alpha - 1 year ago

Madrigal: Beyond NASH

GlobeNewsWire - 1 year ago

-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-c...

GlobeNewsWire - 1 year ago

WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on t...

GlobeNewsWire - 1 year ago

CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the de...

Zacks Investment Research - 1 year ago

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Other stocks mentioned: AGN, CBAY, CNAT, GLMD, ICPT
GlobeNewsWire - 1 year ago

Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH:

GlobeNewsWire - 1 year ago

CONSHOHOCKEN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights:

The Motley Fool - 1 year ago

Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.

Other stocks mentioned: ASMB, CBAY
The Motley Fool - 1 year ago

Which of these NASH-oriented biotechs is the better buy?

Other stocks mentioned: ICPT
Seeking Alpha - 1 year ago

Madrigal is one of the more prominent NASH-targeted biopharma companies today.

GuruFocus - 1 year ago

The following securities are falling knives, meaning their share prices have declined more than 59% over the last 52 weeks.

Other stocks mentioned: INGN
Investors Business Daily - 1 year ago

Biotech stocks Intercept Pharmaceuticals and Madrigal Pharmaceuticals were hit Thursday after the Food and Drug Administration cast doubt on a method of evaluating some liver disease drugs.

Other stocks mentioned: ICPT
Investors Business Daily - 1 year ago

Medical technology and biotech stocks were ravaged Wednesday on a "Medicare for All" proposal out of Washington and amid rising popularity for presidential candidate Bernie Sanders.

Other stocks mentioned: DXCM, IONS, ISRG, MASI
Seeking Alpha - 1 year ago

Although possessing huge market opportunities, there is currently no ideal NASH candidate in the late clinical stage.

Seeking Alpha - 1 year ago

Liver Therapy Forum weekly digest provides an overview on what’s happening in the NASH landscape in 2019. This week focuses on Madrigal.

About MDGL

Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical ... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Rebecca Taub
Employees
29
Stock Exchange
NASDAQ
Ticker Symbol
MDGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is 170.00, which is an increase of 55.91% from the latest price.

Price Target
$170.00
(55.91% upside)
Analyst Consensus: Buy